Description: Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecules that combine targeted and immune-mediated mechanisms with the potential to treat various tumors. The company's two novel clinical programs are TPST-1495 and TPST-1120, antagonists of EP2/EP4 and PPARa. Its TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study agents as monotherapies and in combination with other approved agents. The company is also developing an orally-available inhibitor of TREX-1 designed to activate selectively the cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity. The company is headquartered in South San Francisco, California. Tempest Therapeutics Inc. operates as a subsidiary of Inception Sciences, Inc.
Home Page: www.tempesttx.com
TPST Technical Analysis
7000 Shoreline Court
South San Francisco,
CA
94080
United States
Phone:
415 798 8589
Officers
| Name | Title |
|---|---|
| Mr. Stephen R. Brady J.D., LLM | CEO & Director |
| Dr. Thomas W. Dubensky Jr., Ph.D. | Pres & Director |
| Dr. Samuel Whiting M.D., Ph.D. | Exec. VP & Chief Medical Officer |
| Mr. Nicholas Maestas | VP of Strategy & Fin. and Sec. |
| Mr. Justin Trojanowski | Corp. Controller, Treasurer & Principal Accounting Officer |
| Mr. Petpiboon Prasit | Acting Chief Scientific Officer & Exec. Director |
| Dr. Sharon Sakai Ph.D., RAC | Head of Regulatory & Quality |
| Dr. Anne Moon | Sr. VP and Head of Project Team Leadership, Project Management & Portfolio Management |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0.1564 |
| Price-to-Book MRQ: | 0.6148 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2012-11-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 17 |